Our Patients
More than 200 million patients world-wide are affected by neurodegenerative diseases, representing tremendous unmet medical need.
There are currently no medicines that slow or stop the relentless progression of these diseases. Patients experience difficulties remembering, thinking, understanding and moving, diminishing quality of life for them and their loved ones. Understanding how to slow or stop cognitive impairment, and how to enhance resilience to cognitive dysfunction, is the focus of our drug discovery efforts.